Towards 100 Billion Data Points for Advanced Drug Discovery and Treatment Combinations

Lantern Pharma, a NASDAQ-listed company specializing in AI-driven cancer drug discovery and development, has announced a milestone with its artificial intelligence platform for precision medicine, RADR®, aiming at a greater focus on data acquisition and improving oncology drug development.

The company's proprietary AI platform has recently surpassed 60 billion data points, with expectations to reach over 100 billion data points in 2024. This extensive data growth is set to enhance the development of cancer therapies by providing more precise and comprehensive insights into drug-tumor interactions.

The RADR® platform's expansion into analyzing drug sensitivity data, combination treatment outcomes, and biomarker data, especially in rare cancers, underscores Lantern Pharma's commitment to addressing unmet needs in oncology.

By focusing on emerging synthetic lethal targets, the platform aims to fast-track the development of new therapies for Lantern and its collaborative partners. Additionally, enhancements to RADR®'s generative AI capabilities are underway, with a focus on molecular optimization and automated feature extraction to better predict molecular dynamics, safety, and drug-drug interactions.

Since its inception, RADR® has grown rapidly, from under 20 million data points in early 2019 to over 60 billion today. This growth has been facilitated by increasingly automated, machine learning-enabled processes that allow for efficient collection, tagging, and curation of data from diverse sources.

The platform's significant data expansion has played a crucial role in the development of Lantern's drug candidates, LP-184 and LP-284, by enabling the exploration of new indications and accelerating development timelines.

READ MORE: How AI Enables Precision Oncology

Lantern's AI-driven analyses, particularly in the realm of immuno-oncology (IO), are set to provide the company with a strategic edge in the way cancer treatments are developed. By integrating large-scale data from IO studies and clinical trials, RADR® enables more robust multi-omic analysis, guiding the use of Lantern's drug candidates in combination with standard-of-care therapies. This approach not only addresses the challenges of drug resistance and unmet clinical needs but also opens new avenues for the development of effective cancer treatments.

RADR®'s ensemble-based approach, utilizing a library of algorithms for drug-tumor interaction analysis, is instrumental in guiding drug development and yielding new biological insights.

Topics: Biotech Companies